Co-delivery of 5-fluorouracil and oxali-palladium via β-lactoglobulin nano-capsules coated with Low Methoxyl Pectin for colon cancer therapy

Leilabadi-Asl A, Ghalandari B, Divsalar A, Karizak AZ, Haertlé T, Ding X, Saboury AA, Ghorbani F (2023)

Publication Type: Journal article

Publication year: 2023

Journal

Journal of Drug Delivery Science and Technology Apstj

Book Volume: 89

Article Number: 105010

DOI: 10.1016/j.jddst.2023.105010

Abstract

Chemotherapy is associated with serious side effects in terms of its high toxicity. Optimizing nanoscale drug delivery systems offers a way to overcome these side effects in cancer treatment. This research studies the synthesis and optimization of β-lactoglobulin (β-LG) nanocapsules coated with Low Methoxyl Pectin (LMP) for the simultaneous delivery of two major drugs, 5-fluorouracil (5-FU) and Oxali-palladium, used for colon cancer chemotherapy. The current research investigates the co-delivery system's physical characteristics, drug loading, and in vitro drug release, as well as its toxicity against the colon cancer cell line. Our findings show that the present co-delivery system uniformly forms, especially at pH 4.5, and has a size <120 nm, this being well optimized for colon cancer cell pores. Moreover, this co-delivery system demonstrates drug encapsulation efficiency of more than 60% for both drugs. Furthermore, it has shown stability and resistance to low-pH acidic conditions. In contrast, it shows the sensitivity to alkaline conditions, which determines that the co-delivery system is optimized for the colon cancer environment. The in vitro drug release results confirm these findings as the highest release rate is associated with the simulated colon cancer conditions. Hence, the present co-delivery system shows higher cytotoxicity toward colon cancer cell lines when compared to free drugs. An in-depth optimization of the co-delivery system of 5-FU and Oxali-palladium using β-LG and LMP is provided, which promotes the development of a protein-based co-delivery system at the nanoscale. Finally, it can be concluded that the presented co-delivery system is very promising to be used in oral drug delivery for colon cancer treatment.

Authors with CRIS profile

Farnaz Ghorbani Lehrstuhl für Werkstoffwissenschaften (Biomaterialien)

Involved external institutions

Shanghai Jiao Tong University / 上海交通大学 CN China (CN) Kharazmi University IR Iran, Islamic Republic of (IR) University of Tehran IR Iran, Islamic Republic of (IR) Biopolymères Interactions Assemblages (BIA) FR France (FR) Islamic Azad University (IAU) / دانشگاه آزاد اسلامی‎‎ IR Iran, Islamic Republic of (IR)

How to cite

APA:

Leilabadi-Asl, A., Ghalandari, B., Divsalar, A., Karizak, A.Z., Haertlé, T., Ding, X.,... Ghorbani, F. (2023). Co-delivery of 5-fluorouracil and oxali-palladium via β-lactoglobulin nano-capsules coated with Low Methoxyl Pectin for colon cancer therapy. Journal of Drug Delivery Science and Technology, 89. https://dx.doi.org/10.1016/j.jddst.2023.105010

MLA:

Leilabadi-Asl, Amineh, et al. "Co-delivery of 5-fluorouracil and oxali-palladium via β-lactoglobulin nano-capsules coated with Low Methoxyl Pectin for colon cancer therapy." Journal of Drug Delivery Science and Technology 89 (2023).

BibTeX: Download